Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Income from Continuing Operations (2024 - 2025)

Prelude Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 17348000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 48.72% year-over-year to 17348000.0; the TTM value through Dec 2025 reached 104566000.0, up 25.16%, while the annual FY2025 figure was 104566000.0, 25.16% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 17348000.0 at Prelude Therapeutics, up from 20418000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 17348000.0 in Q4 2025 and bottomed at 37164000.0 in Q2 2024.